Neurofibroma Clinical Trial
Official title:
Spinal Tumor Proton Protocol
The purpose of this study is to determine if Proton Therapy can provide effective and safe treatment for Malignant Peripheral Nerve Sheath Tumors of the spine and Neurofibromas of the spine.
Proton therapy may provide the benefits of local control or palliation, while reducing the risk associated with photon radiation, by delivering therapeutic doses to a well-defined target area with significant reduction in the integral dose. A dosimetry comparison of protons and photons at the University of Florida Proton Therapy Institute confirmed the feasibility of proton irradiation of these tumors with less exposure of normal tissue to radiation than expected with photon techniques. This reduced radiation exposure to uninvolved normal tissues is expected to decrease the risk of radiation-induced second malignancies and neoplasms. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01347307 -
Stereotactic Body Radiotherapy for Spine Tumors
|
N/A | |
| Recruiting |
NCT05891847 -
Non-interventional Study of Patients With PN NF1 Starting Selumetinib in Russia
|
||
| Recruiting |
NCT06322342 -
Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent
|
Phase 2 | |
| Completed |
NCT00314119 -
Natural History and Biology of Skin Neurofibromas in Neurofibromatosis Type 1
|
||
| Terminated |
NCT00716469 -
Phase I Clinical Study of the Safety of Photodynamic Therapy (PDT) Using LS11 in Children With Plexiform Neurofibromas
|
Phase 1 | |
| Active, not recruiting |
NCT03820778 -
Whole Body MRI to Identify Atypical Neurofibromas in Patients With NF1
|
N/A | |
| Active, not recruiting |
NCT00924196 -
Natural History Study of Patients With Neurofibromatosis Type I
|
||
| Recruiting |
NCT05199376 -
Evaluation of Percutaneous Cryotherapy in the Treatment of Plexiform Neurofibromas and Unresectable Neurofibromas in Neurofibromatosis Type 1
|
N/A | |
| Completed |
NCT01031901 -
Topical Rapamycin Therapy to Alleviate Cutaneous Manifestations of Tuberous Sclerosis Complex (TSC) and Neurofibromatosis I (NF1)
|
Phase 1 |